Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant DT vs ET and Adjuvant NX in HER2- Luminal B Breast Cancer
NCT03359694Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2017
- Primary completion
- Nov 2019
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of pegylated liposomal doxorubicin, vinorelbine, capecitabine in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
pegylated liposomal doxorubicinvinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03359694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359694.